Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.59 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.59 |
| ▸ | MMP1 | P03956 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422826 | 0.88 | L3MBTL1 (0.68) | EPHX1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL425222 | 0.86 | TRPV1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL22412530 | 0.83 | PLAAT5 (0.75) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL249525 | 0.83 | CA12 (0.68) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL6032606 | 0.83 | EPHX1 (0.85) | CA12CA2CA9EPHX1PLAAT5 | |
| SCHEMBL27711422 | 0.82 | LMNA (0.51) | CA12CA2CA9CA1NPC1 | |
| SCHEMBL1567251 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL9718519 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL4459966 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 | |
| Phenethylcarbamic Acid SCHEMBL28010696 | 0.81 | CA12 (0.66) | CA12CA2CA9EPHX1PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | claimed |
| EP-1802297-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2008-05-28 | — | — | EP | claimed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1802297-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | The Burnham Institute (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006047162-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | THE BURNHAM INSTITUTE (US) | 2006-05-04 | — | — | WO | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1802297-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
| EP-0192255-B1 | BIS-2H-PYRROLIDINE DIONES | CIBA-GEIGY AG (CH) | 1990-08-08 | — | — | EP | disclosed |
| US-4789674-A | ALZHEIMER'S DISEASE, MEMORY, DEMENTIA | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | disclosed |
| US-4758575-A | Bi-2H-pyrroli(di)nediones | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0192255-A2 | Bis-2H-pyrrolidine diones | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | CA12 3972/4885CA2 3841/4885CA9 2263/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CA12 2406/4885CA2 2701/4885CA9 1182/4885 |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | PTPRS, PTPRO, PTPN5 | CA12 2514/4885CA2 758/4885CA9 1873/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CA12 1663/4885CA2 1297/4885CA9 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.